 Stephen Kissler
Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 7 | 2024 | 1925 | 1.620 |
Why?
| | Respiratory Tract Infections | 3 | 2023 | 396 | 1.530 |
Why?
| | Models, Theoretical | 4 | 2026 | 560 | 1.480 |
Why?
| | Pandemics | 14 | 2026 | 1711 | 1.460 |
Why?
| | Pneumonia, Viral | 4 | 2020 | 391 | 1.090 |
Why?
| | Coronavirus Infections | 4 | 2020 | 384 | 1.090 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2020 | 159 | 1.060 |
Why?
| | Influenza, Human | 5 | 2020 | 624 | 1.030 |
Why?
| | Outpatients | 4 | 2024 | 447 | 0.940 |
Why?
| | Policy Making | 1 | 2026 | 83 | 0.920 |
Why?
| | Gonorrhea | 2 | 2021 | 63 | 0.790 |
Why?
| | Transportation | 2 | 2020 | 57 | 0.750 |
Why?
| | Antimicrobial Stewardship | 2 | 2024 | 130 | 0.750 |
Why?
| | Health Policy | 1 | 2026 | 400 | 0.750 |
Why?
| | Endometriosis | 4 | 2007 | 58 | 0.740 |
Why?
| | Betacoronavirus | 4 | 2020 | 289 | 0.690 |
Why?
| | Epidemics | 2 | 2020 | 96 | 0.690 |
Why?
| | Virus Shedding | 1 | 2021 | 49 | 0.670 |
Why?
| | Travel | 2 | 2018 | 136 | 0.630 |
Why?
| | Viral Load | 2 | 2022 | 526 | 0.630 |
Why?
| | Practice Patterns, Physicians' | 3 | 2024 | 1372 | 0.620 |
Why?
| | Communication | 1 | 2026 | 976 | 0.590 |
Why?
| | Social Class | 1 | 2021 | 264 | 0.580 |
Why?
| | Virus Replication | 1 | 2021 | 521 | 0.550 |
Why?
| | RNA, Viral | 2 | 2022 | 692 | 0.550 |
Why?
| | Residence Characteristics | 1 | 2020 | 375 | 0.510 |
Why?
| | Disease Outbreaks | 4 | 2024 | 419 | 0.490 |
Why?
| | Infertility, Female | 3 | 2006 | 122 | 0.480 |
Why?
| | Fallopian Tube Diseases | 2 | 2006 | 6 | 0.470 |
Why?
| | Seasons | 4 | 2024 | 538 | 0.450 |
Why?
| | Drug Resistance, Bacterial | 3 | 2022 | 185 | 0.440 |
Why?
| | Humans | 47 | 2026 | 145750 | 0.430 |
Why?
| | United States | 12 | 2024 | 16122 | 0.410 |
Why?
| | Patient-Specific Modeling | 1 | 2014 | 45 | 0.410 |
Why?
| | Health Status Disparities | 3 | 2022 | 321 | 0.400 |
Why?
| | Kinetics | 3 | 2026 | 1568 | 0.380 |
Why?
| | Models, Biological | 1 | 2020 | 1764 | 0.370 |
Why?
| | Drug Resistance, Microbial | 2 | 2023 | 64 | 0.340 |
Why?
| | Cities | 3 | 2020 | 139 | 0.330 |
Why?
| | Massachusetts | 2 | 2021 | 180 | 0.320 |
Why?
| | Precision Medicine | 1 | 2014 | 461 | 0.300 |
Why?
| | Dysmenorrhea | 1 | 2007 | 7 | 0.260 |
Why?
| | Adenomyoma | 1 | 2006 | 2 | 0.240 |
Why?
| | Communicable Disease Control | 3 | 2022 | 86 | 0.230 |
Why?
| | Ovum Transport | 1 | 2005 | 1 | 0.230 |
Why?
| | Diabetes Mellitus | 1 | 2014 | 1101 | 0.220 |
Why?
| | Vaccination | 2 | 2026 | 1428 | 0.220 |
Why?
| | Uterine Neoplasms | 1 | 2006 | 98 | 0.220 |
Why?
| | Pregnancy Rate | 1 | 2005 | 81 | 0.220 |
Why?
| | New York City | 2 | 2024 | 84 | 0.210 |
Why?
| | Fallopian Tube Patency Tests | 1 | 2004 | 1 | 0.210 |
Why?
| | Sperm Transport | 1 | 2004 | 2 | 0.210 |
Why?
| | HIV Infections | 1 | 2020 | 3195 | 0.210 |
Why?
| | Pharyngitis | 1 | 2024 | 25 | 0.210 |
Why?
| | Fallopian Tubes | 1 | 2004 | 33 | 0.210 |
Why?
| | Uterus | 1 | 2005 | 228 | 0.210 |
Why?
| | Streptococcus pyogenes | 1 | 2024 | 41 | 0.200 |
Why?
| | Blood Glucose | 1 | 2014 | 2344 | 0.200 |
Why?
| | Contact Tracing | 2 | 2020 | 26 | 0.200 |
Why?
| | Patient Isolation | 2 | 2020 | 20 | 0.200 |
Why?
| | Public Health Surveillance | 1 | 2024 | 83 | 0.200 |
Why?
| | Quarantine | 2 | 2020 | 31 | 0.200 |
Why?
| | Medicare Part C | 1 | 2024 | 36 | 0.190 |
Why?
| | Cost-Benefit Analysis | 1 | 2026 | 644 | 0.190 |
Why?
| | Dermatitis | 1 | 2022 | 20 | 0.190 |
Why?
| | Prescriptions | 1 | 2023 | 74 | 0.190 |
Why?
| | Bayes Theorem | 2 | 2021 | 421 | 0.190 |
Why?
| | Child | 8 | 2026 | 22738 | 0.180 |
Why?
| | Incidence | 5 | 2024 | 2933 | 0.180 |
Why?
| | Adult | 15 | 2026 | 40867 | 0.180 |
Why?
| | Drug Prescriptions | 1 | 2024 | 288 | 0.180 |
Why?
| | Knowledge | 1 | 2022 | 57 | 0.180 |
Why?
| | Models, Statistical | 3 | 2021 | 672 | 0.180 |
Why?
| | Streptococcal Infections | 1 | 2024 | 171 | 0.170 |
Why?
| | Convalescence | 1 | 2021 | 19 | 0.170 |
Why?
| | Basketball | 1 | 2021 | 16 | 0.170 |
Why?
| | Bacterial Vaccines | 1 | 2021 | 63 | 0.170 |
Why?
| | Lymphoma | 1 | 2023 | 241 | 0.170 |
Why?
| | Mass Vaccination | 1 | 2021 | 18 | 0.170 |
Why?
| | Health Priorities | 1 | 2021 | 41 | 0.160 |
Why?
| | Young Adult | 6 | 2026 | 14250 | 0.160 |
Why?
| | Neisseria gonorrhoeae | 1 | 2020 | 29 | 0.160 |
Why?
| | Inappropriate Prescribing | 1 | 2021 | 66 | 0.160 |
Why?
| | Coronavirus OC43, Human | 1 | 2020 | 7 | 0.160 |
Why?
| | Social Networking | 1 | 2020 | 32 | 0.160 |
Why?
| | Entropy | 1 | 2020 | 44 | 0.150 |
Why?
| | Communicable Diseases | 1 | 2022 | 166 | 0.150 |
Why?
| | Public Health | 2 | 2024 | 574 | 0.150 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 96 | 0.150 |
Why?
| | Prospective Studies | 5 | 2021 | 8075 | 0.150 |
Why?
| | Disease Transmission, Infectious | 1 | 2020 | 69 | 0.150 |
Why?
| | Models, Economic | 1 | 2020 | 62 | 0.150 |
Why?
| | Genome, Bacterial | 1 | 2020 | 123 | 0.150 |
Why?
| | Ambulatory Care | 1 | 2024 | 610 | 0.150 |
Why?
| | Southeastern United States | 1 | 2018 | 37 | 0.140 |
Why?
| | Urbanization | 1 | 2018 | 28 | 0.140 |
Why?
| | HIV | 1 | 2020 | 251 | 0.140 |
Why?
| | Humidity | 1 | 2018 | 49 | 0.140 |
Why?
| | Biological Evolution | 1 | 2022 | 468 | 0.140 |
Why?
| | Motion Pictures | 1 | 2018 | 20 | 0.130 |
Why?
| | Comorbidity | 1 | 2023 | 1662 | 0.130 |
Why?
| | Athletes | 1 | 2021 | 425 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 2 | 2007 | 3915 | 0.130 |
Why?
| | Research Design | 1 | 2023 | 1139 | 0.130 |
Why?
| | Genes, erbB-2 | 2 | 2007 | 32 | 0.130 |
Why?
| | California | 1 | 2018 | 473 | 0.120 |
Why?
| | United Kingdom | 3 | 2026 | 358 | 0.120 |
Why?
| | Endometrium | 2 | 2007 | 64 | 0.120 |
Why?
| | Seroepidemiologic Studies | 3 | 2021 | 171 | 0.120 |
Why?
| | Spatio-Temporal Analysis | 3 | 2024 | 34 | 0.120 |
Why?
| | Hysterosalpingography | 2 | 2005 | 9 | 0.110 |
Why?
| | Mobile Applications | 1 | 2018 | 199 | 0.110 |
Why?
| | Sperm Injections, Intracytoplasmic | 2 | 2005 | 15 | 0.110 |
Why?
| | Estrogen Receptor beta | 2 | 2005 | 40 | 0.110 |
Why?
| | Adolescent | 8 | 2026 | 22569 | 0.110 |
Why?
| | Prevalence | 2 | 2020 | 2874 | 0.110 |
Why?
| | Genotype | 1 | 2019 | 1857 | 0.110 |
Why?
| | Sulfonylurea Compounds | 1 | 2014 | 51 | 0.100 |
Why?
| | Biological Clocks | 1 | 2014 | 48 | 0.100 |
Why?
| | Fertilization in Vitro | 2 | 2005 | 108 | 0.100 |
Why?
| | Urban Population | 1 | 2017 | 494 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2933 | 0.100 |
Why?
| | Breast Neoplasms | 4 | 2007 | 2393 | 0.100 |
Why?
| | Female | 15 | 2026 | 79025 | 0.090 |
Why?
| | Middle Aged | 10 | 2026 | 36297 | 0.090 |
Why?
| | Male | 6 | 2026 | 72992 | 0.080 |
Why?
| | Aged | 9 | 2026 | 26212 | 0.080 |
Why?
| | Metformin | 1 | 2014 | 329 | 0.080 |
Why?
| | Time Factors | 2 | 2014 | 7133 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2024 | 17322 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2022 | 674 | 0.060 |
Why?
| | Neoplasms | 1 | 2023 | 2913 | 0.060 |
Why?
| | Vulvar Neoplasms | 1 | 2006 | 13 | 0.060 |
Why?
| | Carcinoma in Situ | 1 | 2006 | 44 | 0.060 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2006 | 42 | 0.060 |
Why?
| | Carcinoma, Lobular | 1 | 2006 | 56 | 0.060 |
Why?
| | Quality-Adjusted Life Years | 1 | 2026 | 125 | 0.060 |
Why?
| | HIV Seropositivity | 1 | 2006 | 119 | 0.060 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2006 | 90 | 0.060 |
Why?
| | Integrins | 1 | 2006 | 90 | 0.060 |
Why?
| | tau Proteins | 1 | 2006 | 105 | 0.060 |
Why?
| | Infant | 3 | 2026 | 10089 | 0.060 |
Why?
| | Gene Expression Profiling | 3 | 2007 | 1777 | 0.060 |
Why?
| | Infertility, Male | 1 | 2005 | 80 | 0.060 |
Why?
| | Mass Screening | 2 | 2020 | 1361 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2006 | 271 | 0.050 |
Why?
| | Biomarkers, Tumor | 3 | 2006 | 1329 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 751 | 0.050 |
Why?
| | Technetium | 1 | 2004 | 10 | 0.050 |
Why?
| | Child, Preschool | 3 | 2026 | 11866 | 0.050 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2004 | 61 | 0.050 |
Why?
| | Precancerous Conditions | 1 | 2005 | 166 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2004 | 116 | 0.050 |
Why?
| | Carcinoma | 1 | 2005 | 227 | 0.050 |
Why?
| | Age Factors | 2 | 2021 | 3346 | 0.050 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2006 | 268 | 0.050 |
Why?
| | Estrogen Receptor alpha | 1 | 2004 | 151 | 0.050 |
Why?
| | Insulin | 1 | 2014 | 2516 | 0.050 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2023 | 55 | 0.050 |
Why?
| | Receptors, Progesterone | 1 | 2004 | 244 | 0.050 |
Why?
| | Genome, Viral | 1 | 2024 | 214 | 0.050 |
Why?
| | Methylation | 1 | 2023 | 242 | 0.050 |
Why?
| | Papillomavirus Infections | 1 | 2006 | 344 | 0.040 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2023 | 79 | 0.040 |
Why?
| | Penicillins | 1 | 2022 | 62 | 0.040 |
Why?
| | Macrolides | 1 | 2022 | 67 | 0.040 |
Why?
| | Pregnancy | 2 | 2005 | 7215 | 0.040 |
Why?
| | Immunity, Herd | 1 | 2021 | 7 | 0.040 |
Why?
| | New York | 1 | 2021 | 128 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2005 | 1247 | 0.040 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 37 | 0.040 |
Why?
| | Population Surveillance | 1 | 2024 | 484 | 0.040 |
Why?
| | Basic Reproduction Number | 1 | 2020 | 6 | 0.040 |
Why?
| | DNA Methylation | 1 | 2005 | 690 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2007 | 1969 | 0.040 |
Why?
| | Uncertainty | 1 | 2021 | 146 | 0.040 |
Why?
| | Computational Biology | 1 | 2024 | 669 | 0.040 |
Why?
| | Epidemiological Monitoring | 1 | 2019 | 70 | 0.040 |
Why?
| | Disease Progression | 1 | 2007 | 2865 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2006 | 1482 | 0.040 |
Why?
| | Minority Groups | 1 | 2021 | 285 | 0.040 |
Why?
| | Genetic Markers | 1 | 2019 | 338 | 0.040 |
Why?
| | Cost of Illness | 1 | 2021 | 324 | 0.040 |
Why?
| | Orthomyxoviridae | 1 | 2018 | 40 | 0.030 |
Why?
| | Population Density | 1 | 2018 | 89 | 0.030 |
Why?
| | Microbial Sensitivity Tests | 1 | 2019 | 365 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2004 | 1166 | 0.030 |
Why?
| | Learning | 1 | 2022 | 444 | 0.030 |
Why?
| | Antigens, Viral | 1 | 2018 | 182 | 0.030 |
Why?
| | Escherichia coli | 1 | 2022 | 835 | 0.030 |
Why?
| | Histones | 1 | 2023 | 666 | 0.030 |
Why?
| | Family | 1 | 2022 | 684 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 1062 | 0.030 |
Why?
| | Human Migration | 1 | 2017 | 25 | 0.030 |
Why?
| | Alphapapillomavirus | 2 | 2006 | 35 | 0.030 |
Why?
| | Taxoids | 2 | 2007 | 114 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 789 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2026 | 8346 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2022 | 769 | 0.030 |
Why?
| | Bacteria | 1 | 2022 | 766 | 0.030 |
Why?
| | Cyclophosphamide | 2 | 2007 | 272 | 0.030 |
Why?
| | Hospitalization | 1 | 2026 | 2460 | 0.030 |
Why?
| | Data Collection | 1 | 2018 | 643 | 0.030 |
Why?
| | Evolution, Molecular | 1 | 2018 | 494 | 0.030 |
Why?
| | Doxorubicin | 2 | 2007 | 403 | 0.030 |
Why?
| | Neoadjuvant Therapy | 2 | 2007 | 467 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1330 | 0.020 |
Why?
| | Computer Simulation | 1 | 2017 | 1003 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2024 | 5921 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2021 | 6464 | 0.020 |
Why?
| | Risk Factors | 2 | 2017 | 10916 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2022 | 11793 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3752 | 0.020 |
Why?
| | Uterine Cervical Dysplasia | 1 | 2006 | 27 | 0.020 |
Why?
| | Choristoma | 1 | 2006 | 20 | 0.010 |
Why?
| | Prognosis | 2 | 2005 | 4329 | 0.010 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2006 | 140 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 2005 | 160 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2006 | 427 | 0.010 |
Why?
| | Presenilin-2 | 1 | 2004 | 6 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 2004 | 200 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2006 | 1300 | 0.010 |
Why?
| | Reoperation | 1 | 2006 | 637 | 0.010 |
Why?
| | RNA, Small Interfering | 1 | 2005 | 638 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2006 | 1547 | 0.010 |
Why?
| | Biopsy | 1 | 2006 | 1082 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2171 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2883 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2006 | 2123 | 0.010 |
Why?
| | Epigenesis, Genetic | 1 | 2005 | 693 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2006 | 1150 | 0.010 |
Why?
|
|
Kissler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|